After last week's expert panel meetings, the FDA may put some label limits on PCSK9 cholesterol drugs. But Sanofi ($SNY), Regeneron ($REGN) and Amgen ($AMGN) can take heart. If word from doctor surveys is any indication, those limits won't put a huge damper on sales, because cardiologists are hot to trot to prescribe Praluent, Repatha or both. More from FiercePharmaMarketing